MedTrace Logo

Herbal Medicine 'Eungyosan' and 'Samsoeum' for Common Cold

NCT04073511 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 375

Last updated 2019-09-03

No results posted yet for this study

Summary

The investigators intend to conduct a multicenter clinical trial to verify the effectiveness and safety of the administration of 'Eungyosan(EGS)' and 'Samsoeum(SSE)' in cold patients.

Conditions

  • Common Cold

Interventions

DRUG

Eungyosan

This drug is a commercially available drug, manufactured according to the Preparation of granules, General rule of formulation, Korean Pharmacopoeia. Dosage is 1 packet, 2.3g, 3 times daily, 6.9g total daily dose. The total duration of administration is up to 8 days.

DRUG

Samsoeum

This drug is a commercially available drug, manufactured according to MFDS regulations and the Preparation of granules, General rule of formulation, Korean Pharmacopoeia. 3.37g of a packet, 3 times a day, the total daily dose is 10.11g. Total duration of administration is up to 8 days.

DRUG

Placebo

It is composed of lactose carb, corn starch, caramel pigment, and ginseng flavor powder. It is brown granule and made to be recognized as Korean medicine. Take a total of 9.0g, 3.0g each, three times a day. The total duration of administration is up to 8 days.

Sponsors & Collaborators

  • Korean Medicine Hospital of Pusan National University

    lead OTHER

Principal Investigators

  • Jun-Yong Choi, PhD · Korean Medicine Hospital, Pusan National University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-16
Primary Completion
2020-12-27
Completion
2020-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04073511 on ClinicalTrials.gov